Human Cytochromes P450 and Their Role in Metabolism-Based Drug-Drug Interactions

Drug-Drug Interactions, Second Edition

Volumn , Issue , 2019, Pages 53-86

  Clarke, Stephen E ^a   Jones, Barry C ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85146105957     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780429131967-3     Document Type: Chapter

References (193)

1. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12:1-51.
2. David Nelson Cytochrome P450 Homepage. http://drnelson.utmem.edu/CytochromeP450.html
3. Yamamoto Y, Ishizuka M, Takada A, et al. Cloning, tissue distribution, and functional expression of two novel rabbit cytochrome P450 isozymes, CYP2D23 and CYP2D24 J Biochem 1998; 124:503-508.
4. Zhang QY, Raner G, Ding XX, et al. Characterization of the cytochrome P450 CYP2J4-expression in rat small intestine and role in retinoic acid biotransformation from retinal. Arch Biochem Biophys 1998; 353:257-264.
5. Hiroi T, Imaoka S, Chow T, et al. Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim Biophys Acta 1998; 1380:305-312.
6. Zeldin DC, Foley J, Goldsworthy SM, et al. CYP2J subfamily cytochrome P450s in the gastrointestinal tract-expression, localization, and potential functional significance. Mol Pharmacol 1997; 51:931-943.
7. Zhang QY, Wikoff J, Dunbar D, et al. Regulation of cytochrome P4501A1 expression in rat small intestine. Drug Metab Dispos 1997; 25:21-26.
8. Prueksaritanont T, Gorham LM, Hochman JH, et al. Comparative studies of drugmetabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 1996; 24:634-642.
9. Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450. Crit Rev Toxicol 1991; 21:407-22.
10. Watkins PB, Wrighton SA, Schuetz EG, et al. Identification of gluticoid-inducible cytochromes P-450 in intestinal mucosa of rats and man. J Clin Invest 1987; 90:1871-1878.
11. Kolars JC, Schmiedlin-Ren P, Schuetz JD, et al. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992; 90:1871-1878.
12. Kolars JC, Lown KS, Schmiedlinren P, et al. CYP3A gene-expression in human gut epithelium. Pharmacogenetics 1994; 4:247-259.
13. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22:947-955.
14. Wu CY, Benet LZ, Hebert MF, et al. Differentiation of absorption, first-pass gut and hepatic metabolism in man: studies with cyclosporine. Clin Pharmacol Ther 1995; 58:492-497.
15. Benet LZ, Wu CY, Hebert MF, et al. Intestinal drug-metabolism and anti-transport processes-a potential paradigm shift in oral-drug delivery. J Cont Rel 1996; 39:139-143.
16. Hashimoto Y, Sasa H, Shimomura M, et al. Effects of intestinal and hepaticmetabolism on the bioavailability of tacrolimus in rats. Pharm Res 1998; 15:1609-1613.
17. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995; 23:1315-1324.
18. Lampen A, Zhang Y, Hackbarth I, et al. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 1998; 285:1104-1112.
19. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60:14-24.
20. Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87:1322-1330.
21. Wang SX, Sutfm TA, Baarnhielm C, et al. Contribution of the intestine to the first-pass metabolism of felodipine in the rat. J Pharmacol Exp Ther 1989; 250:632-636.
22. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99:2545-2553.
23. Marathe PH, Salazar DE, Greene DS, et al. Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans. Pharm Res 1995; 12:1716-1721.
24. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33:103-121.
25. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998; 18:251-272.
26. Feldman EB. How grapefruit juice potentiates drug bioavailability. Nutr Rev 1997; 55:398-400.
27. Edwards DJ, Fitzsimmons ME, Schuetz EG, et al. 6/,7/-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999; 65:237-244.
28. Bailey DG, Kreeft JH, Munoz C, et al. Grapefruitjuice-felodipine interaction: effect of naringin and 6/,7/-dihydroxybergamottin in humans. Clin Pharmacol Ther 1998; 64:248-256.
29. He K, Iyer KR, Hayes RN, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998; 11:252-259.
30. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, et al. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25:1228-1233.
31. Fukuda K, Ohta T, Oshima Y, et al. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 1997; 7:391-396.
32. Fukuda K, Ohta T, Yamazoe Y. Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction. Biol Pharm Bull 1997; 20:560-564.
33. Rodrigues AD. Integrated P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57:465-480.
34. Morgan MY, Reshef R, Shah RR, et al. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25:1057-1064.
35. Shah RR, Oates NS, Idle JR, et al. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 1982; 284:295-2999.
36. Oates NS, Shah RR, Idle JR, et al. Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation. Lancet 1981; 1(8224):837-838.
37. Idle JR, Oates NS, Shah RR, et al. Protecting poor metabolizers, a group at high risk of adverse drug reactions. Lancet 1983; 1(8338): 1388.
38. Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513-1518.
39. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:231-238.
40. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 1997; 23:3-25.
41. Catteau A, Bechet YC, Poisson N, et al. Population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47:423-430.
42. Campbell ME, Speilberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42:157-165.
43. Curi-Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994; 269:384-392.
44. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment as indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55:402-411.
45. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21:195-212.
46. Xiaodong S, Gatti G, Bartoli A, et al. Omeprazole does not enhance the metabolism of phenacetin, a marker of CYP1A2 activity, in healthy volunteers. Ther Drug Monit 1994; 16:248-250.
47. Clarke SE, Ayrton AD, Chenery RJ. Characterisation of the inhibition of 1A2 by furafylline. Xenobiotica 1994; 24:517-526.
48. Kunze KL, Trager WF. Isoform selective mechanism based inhibition of human cytochrome P4501A2 by furafylline. Chem Res Toxicol 1993; 6:649-656.
49. Fuhr U, Anders EM, Mahr G, et al. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36:942-948.
50. Kinzig-Schippers M, Fuhr U, Zaigler U, et al. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther 1999; 65:262-274.
51. Nikolaidis P, Walker SE, Dombros N, et al. Single-dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1991; 11:59-63.
52. Robson RA, Begg EJ, Atkinson HC, et al. Comparative effects of ciprofloxacin and lomefloxacin on the oxidative metabolism of theophylline. Br J Clin Pharmacol 1990; 29:491-493.
53. Brosen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45:1211-1214.
54. Von Moltke LL, Greenblatt DJ, Duan SX, et al. Phenacetin O-deethylation by human liver micro-somes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 1996; 128:398-407.
55. Rasmussen BB, Nielsen TL, Brosen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998; 83:240-245.
56. Jeppesen U, Loft S, Poulsen HE, et al. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996; 6:213-222.
57. Lelo A, Miners JO, Robson RA, et al. Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol 1986; 22:183-186.
58. Butler MA, Iwasaki M, Guengerich FP, et al. Human cytochrome P450PA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U 1989; 86:7696-7700.
59. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 471-473.
60. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation clozapine by human liver in vitro. J Pharmacol Exp Ther 1995; 272:984-990.
61. Jones BC, Hawksworth G, Home VA, et al. Putative active site model for CYP2C9 (tolbutamide hydroxylase). Drug Metab Dispos 1996; 24:1-7.
62. Haining RL, Jones JP, Henne KR, et al. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochem J 1999; 38:3285-3292.
63. Haining RL, Hunter AP, Veronese ME, et al. Allelic variants of human cytochrome P450 2C9-baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 13591 mutant forms. Arch Biochem Biophys 1996; 333:447-458.
64. Yamazaki H, Inoue K, Chiba K, et al. Comparative studies on the catalytic roles cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 1998; 56:243-251.
65. Kaminsky LS. Warfarin as a probe of cytochromes P-450 function. Drug Metab Rev 1989; 20:479-87.
66. Zhang Z, Fasco MJ, Huang Z, et al. Human cytochromes P4501A1 and P4501A2— R-warfarin metabolism as a probe. Drug Metab Dispos 1995; 23:1339-1345.
67. Wienkers LC, Wurden CJ, Storch E, et al. Formation of (R)-8-hydroxywarfarin human liver - microsomes - a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996; 24:610-614.
68. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of warfarin drug interactions. Chem Res Toxicol 1992; 5:54-59.
69. Haining RL, Steward DJ, Henne KR, et al. Correlation of the cytochrome-P450 2C9 Leu(359) defect with warfarin sensitivity. FASEB J 1997; 11:130-139.
70. Steward DJ, Haining RL, Henne KR, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7:361-367.
71. Baldwin SJ, Bloomer JC, Smith GJ, et al. Ketoconazole and sulfaphenazole as respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995; 25:261-270.
72. Kunze KL, Wienkers LC, Thummel KE, et al. Warfarin-fluconazole. 1. Inhibition the human cytochrome-P450-dependent metabolism of warfarin by fluconazole vitro studies. Drug Metab Dispos 1996; 24:414-421.
73. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole. 2. A metabolically based drug-interaction-in vivo studies. Drug Metab Dispos 1996; 24:422-428.
74. Kunze KL, Trager WF. Warfarin-fluconazole. 3. A rational approach to management of a metabolically based drug-interaction. Drug Metab Dispos 1996; 24:429-435.
75. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug-metabolizing cytochrome-P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50:209-215.
76. Transon C, Leemann T, Vogt N, et al. In vivo inhibition profile of cytochrome P450 (tb) (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58:412-17.
77. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31:124-130.
78. Dickerson RG, Hooper WD, Patterson M, et al. Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. Ther Drug Monit 1985; 7:283-289.
79. Tassaneeyakul W, Veronese ME, Birkett DJ, et al. Coregulation of phenytoin and tolbutamide metabolism in humans. Br J Clin Pharmacol 1992; 34:494-498.
80. Thomas RC, Ikeda GJ. The metabolic fate of tolbutamide in man and rat. J Med Chem 1966; 9:507-510.
81. Nelson E, O'Reilly I. Kinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide administration. J Pharmacol Exp Ther 1961; 132:103-109.
82. Veronese ME, Miners JO, Randies D, et al. Validation of the tolbutamide metabolic ratio for population screening with the use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990; 47:403-411.
83. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29:192-209.
84. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 1994; 33:1743-1752.
85. Goldstein JA, De Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-299.
86. Ibeanu GC, Blaisdell J, Ghanayem BI, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998; 8:129-135.
87. Ibeanu GC, Goldstein JA, Meyer U, et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2b) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 1998; 286:1490-1495.
88. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin A'-hydroxylase activity in human liver-microsomes. Br J Clin Pharmacol 1995; 40:481-485.
89. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51:73-78.
90. Andersson T, Miners JO, Veronese ME, et al. Diazepam metabolism by human liver microsomes is mediated by both (5)-mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 1994; 38:131-137.
91. Chiba K, Saitoh A, Koyama E, et al. The role of (S)-mephenytoin A'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme analysis of N-demethylation and 2-hydroxylation. Br J Clin Pharmacol 1994; 37:237-242.
92. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome-P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36:521-530.
93. Tybring G, Bertilsson L. A methodological investigation on the estimation of the (S)-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 1992; 2:241-243.
94. Skjelbo E, Brosen K, Hallas J, et al. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49:18-23.
95. Skjelbo E, Gram LF, Brosen K. The N-demethylation of imipramine correlates with the oxidation of (5)-mephenytoin (S/R ratio). A population study. Br J Clin Pharmacol 1993; 35:331-334.
96. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57:662-669.
97. Alvan G, Bechtel B, Iselius L, et al. Hydroxylation polymorphism of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-537.
98. Sohn DR, Shin SG, Park CW, et al. Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br J Clin Pharmacol 1991; 32:504-507.
99. Dahl ML, Johansson I, Bertilsson L, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274:516-520.
100. Leathart JS, London SJ, Steward A, et al. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998; 8:529-541.
101. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44:2089-2098.
102. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34:262-265.
103. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34:256-261.
104. Von Moltke LL, Greenblatt DJ, Cotreaubibbo MM, et al. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake inhibitor antidepressants, and by quinidine and ketoconazole—a model system to predict drug-interactions in vivo. J Pharmacol Exp Ther 1994; 268:1278-1283.
105. Belpaire FM, Wijnant P, Temmerman A, et al. The oxidative metabolism of metoprolol in human liver microsomes-inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998; 54:261-264.
106. Zapotoczky HG, Simhandl CA. Interactions of antidepressants. Wien Klin Wochenschr 1995; 107:293-300.
107. Brosen K. Are pharmacokinetic drug-interactions with the SSRIs an issue. Int Clin Psychopharmacol 1996; 11:23-27.
108. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors-clinical relevance. Pharmacol Toxicol 1996; 78:203-208.
109. Ereshefsky L, Riesenman C, Lam YWF. Serotonin selective reuptake inhibitor druginteractions and the cytochrome-P450 system. J Clin Psychiatry 1996; 57:17-25.
110. Lane RM. Pharmacokinetic drug-interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996; 11:31-61.
111. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome. J Clin Psychopharmacol 1997; 17:208-221.
112. Lopezmunoz F, Alamo C, Cuenca E, et al. Effect of antidepressant drugs on cytochrome-P-450 isoenzymes and its clinical relevance-differential profile. Actas Luso Esp Neurol Psiquiatr Cieñe Afines 1997; 25:397-409.
113. Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf 1997; 17:390-406.
114. Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions-a critical review of the evidence. Clin Pharmacokinet 1997; 33:454-471.
115. Baker GB, Fang J, Sinha S, et al. Metabolic drug interactions with selective serotonin reuptake inhibitor (SSRI) antidepressants. Neurosci Biobehav Rev 1998; 22:325-333.
116. Caccia S. Metabolism of the newer antidepressants-an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34:281-302.
117. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450-high-risk associated with ritonavir. J Clin Pharmacol 1998; 38:106-111.
118. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977; 2:584-586.
119. Angelo M, Dring LG, Lancaster R, et al. A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine. Br J Pharmacol 1975; 55:264.
120. Smith RL. Introduction. Xenobiotica 1986; 16:361-365.
121. Gut J, Catin T, Dayer P, et al. Debrisoquine/sparteine type polymorphism of drug oxidation. J Biol Chem 1986; 261:11734-11743.
122. Dayer P, Leemann T, Striberni R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 dbl activity. Clin Pharmacol Ther 1989; 45:34-40.
123. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquine hydroxylation. Clin Pharmacol Ther 1985; 38:618-624.
124. Otton SV, Crewe HK, Lennard MS, et al. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 1988; 247:242-247.
125. McGourty JC, Silas JH, Lennard MS, et al. Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. Br J Clin Pharmacol 1985; 20:555-566.
126. Lennard MS, Iyun AO, Jackson PR, et al. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
127. Schwab GE, Raucy JL, Johnson EF. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 1988; 33:493-99.
128. Shou M, Grogan J, Mancewicz JA, et al. Activation of CYP3A4-evidence for the simultaneous binding of 2 substrates in a cytochrome-P450 active site. Biochemistry 1994; 33:6450-6455.
129. Ueng YF, Kuwabara T, Chun YJ, et al. Cooperativity in oxidations catalyzed by cytochrome-P450 3A4. Biochemistry 1997; 36:370-381.
130. Korzekwa KR, Krishnamachary N, Shou M, et al. Evaluation of atypical cytochrome-P450 kinetics with 2-substrate models-evidence that multiple substrates can simultaneously bind to cytochrome-P450 active sites. Biochemistry 1998; 37:4137-4147.
131. Ekins S, Ring BJ, Binkley SN, et al. Autoactivation and activation of the cytochrome P450s. Int J Clin Pharmacol Ther 1998; 36:642-651.
132. Koley AP, Buters JTM, Robinson RC, et al. CO Binding kinetics of human cytochrome-P450 3A4-specific interaction of substrates with kinetically distinguishable conformers. J Biol Chem 1995; 270:5014-5018.
133. Koley AP, Robinson RC, Friedman FK. Cytochrome-P450 conformation and substrate interactions as probed by CO binding-kinetics. Biochimie 1996; 78:706-713.
134. Koley AP, Robinson RC, Markowitz A, et al. Drug-drug interactions effect of quinidine on nifedipine binding to human cytochrome-P450 3A4. Biochem Pharmacol 1997; 53:455-460.
135. Koley AP, Buters JTM, Robinson RC, et al. Differential mechanisms of cytochrome-P450 inhibition and activation by alpha-naphthoflavone. J Biol Chem 1997; 272:3149-3152.
136. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-1229.
137. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102:1016-1023.
138. Ogg MS, Gray TJ, Gibson GG. Development of an in vitro reporter gene assay to assess xenobiotic induction of the human CYP3A4 gene. Eur J Drug Metab Pharmacokinet 1997; 22:311-313.
139. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59:7-13.
140. Villikka K, Kivisto KT, Backman JT, et al. Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 1997; 61:8-14.
141. Dommisse J. Oral contraceptive failure due to drug interaction. S Afr Med J 1976; 50:796.
142. Back DJ, Breckenridge AM, Crawford FE, et al. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception 1980; 21:135-143.
143. Fazio A. Oral contraceptive drug interactions: important considerations. South Med J 1991; 84:997-1002.
144. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14:13-34.
145. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32:915-928.
146. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18:83-97.
147. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10:63-79.
148. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996; 37:133-142.
149. He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther 1999; 288:791-797.
150. Voorman RL, Maio SM, Payne NA, et al. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 1998; 287:381-388.
151. Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998; 26:552-561.
152. Galetin A, Burt H, Gibbons L, et al. Prediction of time-dependent CYP3A4 drugdrug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006; 34:166-175.
153. Spoendlin M, Peters J, Welker H, et al. Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients. Nephrol Dial Transplant 1998; 13:1787-1791.
154. Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351:1929-1930.
155. Mullins ME, Horowitz BZ, Linden DH, et al. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers. JAMA 1998; 280:157-158.
156. Roche, FDA announce new drug-interaction warnings for mibefradil. Am J Health Syst Pharm 1998; 55:210.
157. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucurocorticoid-inducible liver cytochromes P450. J Clin Invest 1989; 83:688-697.
158. Watkins PB, Hamilton TA, Annesley TM, et al. The erythromycin breath test as a predictor of cyclosporin A blood levels. Clin Pharmacol Ther 1990; 48:120-129.
159. Yun CH, Wood M, Wood AJJ, et al. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-4503A4. An explanation of the variable elimination clearance. Anesthesiology 1992; 77:467-474.
160. Krivoruk Y, Kinirons MT, Wood AJJ, et al. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994; 56:608-614.
161. Lown KS, Thummel KE, Benedict PE, et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995; 57:16-24.
162. Thummel KE, Shen DD, Carithers RL, et al. Prediction of in vivo midazolam clearance from hepatic CYP3A content and midazolam 1-hydroxylation activity in liver transplant patients. ISSX Proc 1993; 4:235.
163. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe: 1. in vitro—in vivo correlations inliver transplant patients. J Pharmacol Exp Ther 1994; 271:549-556.
164. Thummel KE, Shen DD, Bacchi CE, et al. Induction of human hepatic P4503A3/4 by phenytoin. Hepatology 1992; 16:160A.
165. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53:298-305.
166. Ahonen J, Olkkola KT, Neuvonen PJ. Effects of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br Clin Pharmacol 1995; 40:270-272.
167. Guengerich FP, Martin MV, Beaune PH, et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261:5051-5060.
168. Bork RW, Muto T, Beaune PH, et al. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J Biol Chem 1989; 264:910-919.
169. Tailor SA, Gupta AK, Walker SE, et al. Peripheral edema due to nifedipine itraconazole interaction: a case report. Arch Dermatol 1996; 132:350.
170. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337:268-269.
171. Schellens JH, van der Wart JH, Brugman M, et al. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. J Pharmacol Exp Ther 1989; 249:638-645.
172. Holtbecker N, Fromm MF, Kroemer HK, et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996; 24: 1121-1123.
173. Ekins S, VandenBranden M, Ring BJ, et al. Examination of purported probes of human CYP2B6. Pharmacogenetics 1997; 7:165-179.
174. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28:1176-1183.
175. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000; 28:1222-1230.
176. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003; 306:287-300.
177. Huang Z, Roy P, Waxman DJ. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 2000; 59:961-972.
178. Court MH, Duan SX, Hesse LM, et al. Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 2001; 94:110-119.
179. Oda Y, Hamaoka N, Hiroi T, et al. Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 2001; 51:281-285.
180. Turpeinen M, Nieminen R, Juntunen T, et al. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004; 32:626-631.
181. Richter T, Murdter TE, Heinkele G, et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004; 308:189-197.
182. Turpeinen M, Tolonen A, Uusitalo J, et al. Effect of Clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther 2005; 77:553-559.
183. Turpeinen M, Nieminen R, Juntunen T, et al. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004; 32:626-631.
184. Melet A, Marques-Soares C, Schoch GA, et al. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry 2004; 43:15379-15392.
185. Niemi M, Backman JT, Granfors M, et al. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003; 46:1319-1323.
186. Jaakkola T, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 2005; 77:404-414.
187. Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005; 61:831-836.
188. Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003; 46:347-351.
189. Backman JT, Kyrklund C, Neuvonen M, et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72:685-691.
190. Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 2006; 34:191-197.
191. Yamazaki M, Li B, Louie SW, et al. Effects of fibrates on human organic aniontransporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoproteinmediated transport. Xenobiotica 2005; 35:737-753.
192. Niemi M, Kajosaari LI, Neuvonen M, et al. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004; 57:441-47.
193. Niemi M, Backman JT, Neuvonen PJ. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin Pharmacol Ther 2004; 76:239-249.